Surrogate endpoints for neonatal outcome: A rapid review
- PMID: 39100713
- PMCID: PMC11295175
- DOI: 10.1002/hsr2.2279
Surrogate endpoints for neonatal outcome: A rapid review
Keywords: preterm birth; review; strength of association; surrogate endpoints; time to delivery.
Conflict of interest statement
Shiraz El Adam, Karissa Johnston, and Maanasa Venkataraman are employees of Broadstreet HEOR and received consultancy fees from Organon. Vanessa Perez Patel is an employee of Organon.
Figures
References
-
- U.S. Food and Drug Administration . Table of surrogate endpoints that were the basis of drug approval or licensure. 2022. https://www.fda.gov/drugs/development-resources/table-surrogate-endpoint...
-
- Saade GR, Shennan A, Beach KJ, et al. Randomized trials of retosiban versus placebo or atosiban in spontaneous preterm labor. Am J Perinatol. 2021;38(S 01):e309‐e317. - PubMed
LinkOut - more resources
Full Text Sources
